A Phase 1/2 Randomized, Umbrella Study to Evaluate the Safety and Efficacy of Pembrolizumab Plus Enfortumab Vedotin (EV) in Combination With Investigational Agents Versus Pembrolizumab Plus EV, as First-Line Treatment for Participants With Advanced Urothelial Carcinoma (KEYMAKER-U04): Substudy 04B

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Type of Study

Treatment

Locations

University of Colorado Hospital

Principal Investigator
Photograph of Thomas Flaig,  MD

Thomas Flaig, MD

Study ID

Protocol Number: 22-2055B

More information available at ClinicalTrials.gov: NCT05845814

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers